Spreeha Choudhury

Jul 21, 2024 | pharmacytimes.com | Spreeha Choudhury

The Centers for Medicare and Medicaid Services (CMS) has released pharmacy-specific frequently asked questions regarding the upcoming National Coverage Determination (NCD) for pre-exposure prophylaxis (PrEP) to prevent HIV.1 Expected to be effective in late September 2024, the NCD aims to shift Medicare coverage for PrEP products from Part D to Part B.2 This change is intended to allow patients to receive PrEP either at a physician’s office or a pharmacy, enhancing accessibility and convenience.

Jun 13, 2024 | pharmacytimes.com | Spreeha Choudhury

IntroductionThe Advisory Committee on Immunization Practices (ACIP) has recently embraced shared clinical decision-making (SCDM) as a framework for certain vaccine recommendations.

Jan 26, 2024 | healthaffairs.org | Spreeha Choudhury

In October 2023, the Advisory Committee on Immunization Practices (ACIP) unveiled a proposal to reassess the adolescent schedule for meningococcal vaccines. As a key part of this reexamination, the ACIP indicated its intent to address several critical questions. This included a suggestion to completely eliminate the current routine recommendation for 11–12-year-olds to receive the MenACWY vaccine or to modify the recommendation to a shared clinical decision-making approach.

Nov 20, 2023 | healthaffairs.org | Spreeha Choudhury |Richard Hughes IV

On October 4, 2023, the Departments of Health and Human Services, Labor, and the Treasury issued an Request for Information (RFI) aimed at garnering input on enhanced coverage and access to over-the-counter (OTC) preventive services.

Nov 17, 2023 | healthcarebusinesstoday.com | Spreeha Choudhury |Richard Hughes IV

On October 5, 2023, the Vaccines and Related Biologic Products Advisory Committee (VRBPAC), an advisory panel to the Food and Drug Administration (FDA), voted unanimously to remove the B/Yamagata viral strain from future influenza vaccines “as soon as possible.” This change will not be effectuated overnight and, without clearer regulatory guidance, may lead to consumer and provider confusion over the appropriate flu vaccine.